Physician profile
Hussein T Anan
NPI 1386057966
$2,261.40
in general payments reported to CMS, 2019-2025
13 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $24.21 · 2023: $1,377 · 2024: $98.28 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,057.66 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $633.25 | 2019-2025 | Yeztugo |
| Orexo US, INC. | $112.00 | 2023-2024 | Zubsolv |
| Glaxosmithkline, LLC. | $102.72 | 2019 | |
| Abbvie INC. | $79.78 | 2023 | Mavyret, Vraylar |
| Hologic Sales and Service, LLC | $57.27 | 2024-2025 | Aptima |
| Emd Serono, INC. | $55.22 | 2023 | Serostim |
| Exact Sciences Corporation | $40.61 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.09 | 2023 | Delstrigo, Pifeltro |
| Alkermes, INC. | $26.32 | 2023 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.42 | 2023 | Jardiance, Glyxambi, Synjardy |
| Napo Pharmaceuticals INC | $20.79 | 2023 | Mytesi |
| Janssen Biotech, INC. | $15.27 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Anan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.